39 studies found for:    TH-302
Show Display Options
RSS Create an RSS feed from your search for:
TH-302
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib in Subjects With Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: TH-302;   Drug: TH-302 and bortezomib
2 Active, not recruiting A Phase 1 TH-302 Mass Balance Trial
Condition: Solid Tumor
Interventions: Drug: [14C] TH-302 (Label 1);   Drug: [14C] TH-302 (Label 2);   Drug: Unlabeled TH-302
3 Active, not recruiting Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors
Conditions: Advanced Renal Cell Carcinoma;   Gastrointestinal Stromal Tumors;   Pancreatic Neuroendocrine Tumors
Intervention: Drug: TH-302
4 Recruiting A Cardiac Safety Study of TH-302 in Patients With Advanced Solid Tumors
Condition: Solid Tumors
Intervention: Drug: TH-302
5 Active, not recruiting A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
Condition: Soft Tissue Sarcoma
Interventions: Drug: TH-302 in Combination with Doxorubicin;   Drug: Doxorubicin
6 Recruiting Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
Condition: Non-small Cell Lung Cancer
Interventions: Drug: TH-302 combination with pemetrexed;   Drug: Matched placebo in combination with pemetrexed
7 Recruiting Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab
Condition: HIGH GRADE GLIOMA
Interventions: Drug: TH-302;   Drug: Placebo
8 Completed Dose-Escalation Study of TH-302 in Combination With Doxorubicin to Treat Patients With Advanced Soft Tissue Sarcoma
Condition: Soft Tissue Sarcoma
Intervention: Drug: TH-302
9 Active, not recruiting Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors
Conditions: Non-Small Cell Lung Cancer;   Prostate Cancer;   Pancreatic Cancer
Intervention: Drug: TH-302
10 Recruiting A Japanese Phase 1 Trial of TH-302 in Subjects With Solid Tumors and Pancreatic Cancer
Conditions: Solid Tumor;   Pancreatic Cancer
Interventions: Drug: TH-302 monotherapy;   Drug: TH-302;   Drug: Gemcitabine
11 Not yet recruiting TH-302 Plus Doxorubicin Delivered by Trans-Arterial Chemoembolization (TACE) in Patients With Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma
Interventions: Drug: Phase I Dose level -1;   Drug: Phase I dose level 1;   Drug: Phase I Dose level 2;   Drug: Phase I Dose level 3
12 Recruiting A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma
Condition: Metastatic Melanoma
Intervention: Drug: TH-302
13 Completed Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias
Conditions: Acute Myelogenous Leukemia;   Acute Lymphoblastic Leukemia;   Chronic Myelogenous Leukemia;   High-risk Myelodysplastic Syndrome;   Chronic Lymphocytic Leukemia;   Advanced Myelofibrosis
Intervention: Drug: TH-302
14 Active, not recruiting Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma
Condition: Pancreatic Adenocarcinoma
Interventions: Drug: Gemzar (Gemcitabine);   Drug: TH-302
15 Recruiting Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma
Condition: Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma
Interventions: Drug: TH-302;   Drug: Gemcitabine;   Drug: Placebo (5 percent dextrose - D5W)
16 Recruiting Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Drug: TH-302;   Drug: Nab-paclitaxel;   Drug: Gemcitabine
17 Recruiting Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery
Conditions: Kidney Cancer;   Liver Cancer
Interventions: Drug: hypoxia-activated prodrug TH-302;   Drug: sorafenib tosylate;   Genetic: protein analysis;   Other: laboratory biomarker analysis
18 Completed A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
Conditions: Tumors;   Hypoxia
Intervention: Drug: TH-302
19 Active, not recruiting Dose Escalation Study of Pazopanib Plus TH-302
Condition: Solid Tumors
Intervention: Drug: Pazopanib and TH-302
20 Active, not recruiting Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer
Condition: Breast Neoplasms
Interventions: Drug: doxorubicine, cyclophosphamide, docetaxel;   Drug: doxorubicine, cyclophosphamide, trastuzumab, docetaxel;   Drug: trastuzumab, docetaxel, carboplatin

Previous Page Studies Shown (1-20) Next Page (21-39) Show next page of results
Indicates status has not been verified in more than two years